Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Exploring the regenerative and immunomodulatory potential of adipose-derived mesenchymal stem cells in gastroenterology and beyond.

Pelanda H., Fargnoli G., Matteo MV., Amiri Y., Pontecorvi V., Bove V.

Narrative Review on Immune Modulation, published in Expert Rev Gastroenterol Hepatol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Expert Rev Gastroenterol Hepatol (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41378684
DOI
10.1080/17474124.2025.2591247

Abstract (original English)

Introduction Adipose-derived mesenchymal stem cells (ADMSCs) are being increasingly explored in regenerative medicine because of their accessibility and potent immunomodulatory properties. Their application is gaining traction in gastroenterology, where inflammation and tissue degeneration are central to disease progression. Areas covered This review aims to provide an in-depth overview of the biological mechanisms, therapeutic effects, and clinical applications of ADMSCs, focusing on gastrointestinal disorders. We conducted a narrative literature review of relevant studies in PubMed, Google Scholar, and Scopus, covering key findings from gastroenterology, cardiology, neurology, orthopedics, and plastic surgery (editor comment#4b). Original studies evaluating ADMSCs use in gastroenterology and related medical fields were included. Data were organized to illustrate the cellular pathways, cytokine profiles, and paracrine signaling mechanisms through which ADMSCs exert therapeutic effects. ADMSCs consistently reduced inflammation, enhanced tissue repair, and modulated immune responses. Expert opinion In gastroenterology, ADMSCs have demonstrated potential in the treatment of inflammatory bowel disease and liver disorders by promoting mucosal healing and limiting fibrosis. They hold significant promise because of their robust immunomodulatory and regenerative properties. Future stu

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansMesenchymal Stem Cell TransplantationMesenchymal Stem CellsAdipose TissueAnimalsRegenerative MedicineImmunomodulationGastroenterologyGastrointestinal DiseasesTreatment Outcome

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research